Table 5.

Simple and multiple Cox proportional hazards models for 5-year MSS in 101 advanced melanoma patients treated with first-line anti-PD-1-based immunotherapy.

	Simple cox model		Multiple cox model
	HR (95% CI)	p value	HR (95% CI)	p value
eTILs(%)
≤12.2	1.58 (1.15–2.20)	0.0055	1.52 (1.09–2.11)	0.0130
>12.2	–		–
Age at therapy (yrs)
≤65	1.08 (0.57–2.01)	0.8211	NA
>65	–
Age at therapy (yrs)	1.00 (0.97–1.02)	0.8426	NA
Sex
Male	–		–
Female	1.39 (1.02–1.89)	0.0381	1.22 (0.88–1.68)	0.2279
Type of anti-PD-1 therapy
Monotherapy	1.55 (0.79–3.05)	0.2047	NA
Combination	–
BRAF mutation
Wt	1.40 (0.67–2.94)	0.3780	NA
Mutant	–
Brain Metastases
Yes	1.12 (0.75–1.69)	0.5726	NA
No	–
LDH at therapy start: U/l
≤250	–
>250	1.23 (0.65–2.32)	0.5195	NA
LDH at therapy start; U/l	1.01 (1.01–1.01)	<0.0001	1.01 (1.01–1.01)	<0.0001